Want to join the conversation?
Specialty pharmaceutical company $DEPO said that clinical results from Phase IIb trial of GRT6005 (cebranopadol) conducted by Grunenthal GmbH in patients with moderate to severe chronic lower back pain (cLBP) have been posted to the European Clinical Trials Database. Results showed significant improvements in pain at all three doses tested.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.